ESH MM 2018 | CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079

Niels van de Donk

Following the success of daratumumab, a range of other anti-CD38 antibodies are being investigated for multiple myeloma (MM). Here, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses three new such antibodies: isatuximab, MOR202 and TAK-079. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Share this video